BioCentury
ARTICLE | Financial News

Chinese biotech KBP raises $76 million series A

January 5, 2018 1:06 PM UTC

KBP Biosciences Co. Ltd. (Jinan, China) raised a $76 million series A round co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay City Capital GF XINDE Life Science Investment Fund, Efung Capital, CASH Capital, Cowin Capital Group, Korea Investment Partners and Elite Capital.

KBP plans to start Phase IIb testing this year of KBP-5074, a non-steroidal mineralocorticoid receptor antagonist, to treat cardiovascular disease. The company's KBP-7072, an aminomethylcycline, has completed Phase I testing and has Qualified Infectious Disease Product (QIDP) and Fast Track designations from FDA to treat community-acquired bacterial pneumonia (CABP)...

BCIQ Company Profiles

Bay City Capital